Search for: "v. Teva Pharmaceuticals USA, Inc." Results 141 - 160 of 440
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
4 May 2017, 8:26 am by Eric Caligiuri
(“Helsinn”) brought suit against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. [read post]
1 May 2017, 12:44 pm by Gene Quinn
Teva Pharmaceuticals USA, Inc., the Federal Circuit panel of Judges Dyk, Mayer and O’Malley determined: “after the AIA, if the […] The post CAFC Interprets AIA On-Sale Bar: Invention details need not be public for sale to be invalidating appeared first on... [read post]
12 Apr 2017, 7:13 am by Docket Navigator
Teva Pharmaceuticals USA, Inc. et al, 2-15-cv-01455 (TXED April 10, 2017, Order) (Bryson, CJ) [read post]
8 Mar 2017, 8:03 pm by Lawrence B. Ebert
Because we see no error in these rulings, we affirmthe district court’s entry of judgment against Sprint.Teva gets cited as to "claim construction":The proper construction of a patent’s claims is an issueof Federal Circuit law, and we apply the frameworkset forth in Teva Pharmaceuticals USA, Inc. v. [read post]
16 Jan 2017, 5:44 pm by Dennis Crouch
Teva Pharmaceuticals USA, Inc., et al. [read post]
12 Jan 2017, 12:42 pm by Lawrence B. Ebert
;Teva Pharmaceuticals USA, Inc.; and Barr Laboratories,Inc. [read post]
9 Jan 2017, 9:36 am by Lawrence B. Ebert
In other words, Copaxone should remain a $4 billion drug, annually.link to Pantagraph: http://www.pantagraph.com/business/investment/markets-and-stocks/factors-that-sent-teva-pharmaceutical-industries-ltd-sliding-in/article_74234eee-a5ec-5c58-a54b-82597151b1e6.htmlPatents covering "three per week" dosing were not at issue in the Supreme Court case of Teva Pharmaceuticals USA, Inc. v. [read post]
19 Nov 2016, 4:48 am by Gregory B. Williams
Teva Pharmaceuticals USA, Inc., Civil Action No. 14-874-SLR (D.Del., November 16, 2016), the Court found the asserted claims of U.S. [read post]
24 Apr 2016, 9:02 pm by Patent Docs
Teva Pharmaceuticals USA Inc. et al. v. [read post]